Vaginal Health Test

The Tiny Health Vaginal Health Test provides the most comprehensive assessment of the vaginal microbiome available, powered by deep shotgun metagenomics. This approach delivers species- and strain-level resolution across 120,000+ microbial genomes — bacteria, fungi, viruses, and parasites — down to 0.005% relative abundance, along with functional profiling and community state type (CST) classification based on Lactobacillus species dominance. All samples are processed in a CLIA- and CAP-certified U.S. lab, with results delivered in approximately 3–4 weeks. The test ships in discreet packaging labeled "Women's Microbiome Test" for patient privacy.

A Lactobacillus-dominant vaginal microbiome is associated in current research literature with reduced infection risk, healthier reproductive outcomes, and a more favorable environment for conception and pregnancy. Vaginal dysbiosis — characterized by reduced Lactobacillus and elevated potentially pathogenic bacteria — is associated with increased susceptibility to bacterial vaginosis, yeast infections, and adverse reproductive outcomes. Research indicates that women who deliver preterm tend to have lower protective Lactobacillus levels and higher pathogenic bacterial loads; high Lactobacillus crispatus levels at 16 weeks of pregnancy have been associated with protective effects against preterm birth in published literature. The Vaginal Health Test surfaces these dynamics with precision — identifying specific Lactobacillus species levels, pathobionts, organisms associated with BV and yeast infections, and microbiome markers relevant to fertility and pregnancy outcomes — and translates findings into evidence-based probiotic, dietary, and lifestyle recommendations.

This test is recommended for patients trying to conceive or undergoing fertility treatment such as IUI or IVF, where vaginal microbiome optimization may support implantation outcomes; pregnant patients preparing for healthy microbial seeding at birth; patients with recurrent BV or yeast infections where targeted root-cause analysis can support lasting resolution; women experiencing unexplained pelvic symptoms where standard infection workup is inconclusive; and patients in perimenopause or postmenopause, where hormonal shifts directly impact vaginal microbiome composition.